English Overview
Amyloid-Targeting Therapy in Early Symptomatic AD: Treat to Clear
This Activity for
- Resident / Fellow
- Physician
What I will learn?
By the end of the Kisunla (donanemab) event, on 19 October 2026, at least 80% of attending healthcare professionals will be able to identify appropriate patients with early symptomatic Alzheimer's disease per the SFDA-approved label, describe the required MRI monitoring schedule and ARIA management approach, and outline the approved dosing and administration requirements — measured by improvement between pre- and post-event knowledge assessments.
Additional items to the activity
| Optional Details | Type | Fee |
|---|---|---|
|
Amyloid-Targeting Therapy in Early Symptomatic AD
Certificate |
Certificate | Free |
